Literature DB >> 33807930

Orally Administered NSAIDs-General Characteristics and Usage in the Treatment of Temporomandibular Joint Osteoarthritis-A Narrative Review.

Marcin Derwich1, Maria Mitus-Kenig2, Elzbieta Pawlowska3.   

Abstract

Background: Temporomandibular joint osteoarthritis (TMJ OA) is a degenerative joint disease. The aim of this review was to present the general characteristics of orally administered nonsteroidal anti-inflammatory drugs (NSAIDs) and to present the efficacy of NSAIDs in the treatment of TMJ OA.
Methods: PubMed database was analyzed with the keywords: "(temporomandibular joint) AND ((disorders) OR (osteoarthritis) AND (treatment)) AND (nonsteroidal anti-inflammatory drug)". After screening of 180 results, 6 studies have been included in this narrative review. Results and Conclusions: Nonsteroidal anti-inflammatory drugs are one of the most commonly used drugs for alleviation of pain localized in the orofacial area. The majority of articles predominantly examined and described diclofenac sodium in the treatment of pain in the course of TMJ OA. Because of the limited number of randomized studies evaluating the efficacy of NSAIDs in the treatment of TMJ OA, as well as high heterogeneity of published researches, it seems impossible to draw up unequivocal recommendations for the usage of NSAIDs in the treatment of TMJ OA. However, it is highly recommended to use the lowest effective dose of NSAIDs for the shortest possible time. Moreover, in patients with increased risk of gastrointestinal complications, supplementary gastroprotective agents should be prescribed.

Entities:  

Keywords:  NSAID; temporomandibular joint osteoarthritis; treatment of temporomandibular joint disorders

Year:  2021        PMID: 33807930      PMCID: PMC7998670          DOI: 10.3390/ph14030219

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  80 in total

1.  Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.

Authors:  A Lanas; L A García-Rodríguez; M T Arroyo; F Gomollón; F Feu; A González-Pérez; E Zapata; G Bástida; L Rodrigo; S Santolaria; M Güell; C M de Argila; E Quintero; F Borda; J M Piqué
Journal:  Gut       Date:  2006-05-10       Impact factor: 23.059

Review 2.  Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach.

Authors:  Jaismy Jacob P; S L Manju; K R Ethiraj; Geetha Elias
Journal:  Eur J Pharm Sci       Date:  2018-06-05       Impact factor: 4.384

Review 3.  Pharmacotherapy in Temporomandibular Disorders: A Review.

Authors:  Aviv Ouanounou; Michael Goldberg; Daniel A Haas
Journal:  J Can Dent Assoc       Date:  2017-07       Impact factor: 1.316

4.  Prevalence of degenerative joint disease of the temporomandibular joint: a systematic review.

Authors:  Leticia Lopes Quirino Pantoja; Isabela Porto de Toledo; Yasmine Mendes Pupo; André Luís Porporatti; Graziela De Luca Canto; Liete Figueiredo Zwir; Eliete Neves Silva Guerra
Journal:  Clin Oral Investig       Date:  2018-10-11       Impact factor: 3.573

Review 5.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

6.  Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.

Authors:  Zhang Li; Zhong-Chang Wang; Xin Li; Muhammad Abbas; Song-Yu Wu; Shen-Zhen Ren; Qi-Xing Liu; Yi Liu; Peng-Wen Chen; Yong-Tao Duan; Peng-Cheng Lv; Hai-Liang Zhu
Journal:  Eur J Med Chem       Date:  2019-03-08       Impact factor: 6.514

7.  Topical versus systemic diclofenac in the treatment of temporo-mandibular joint dysfunction symptoms.

Authors:  L Di Rienzo Businco; A Di Rienzo Businco; M D'Emilia; M Lauriello; G Coen Tirelli
Journal:  Acta Otorhinolaryngol Ital       Date:  2004-10       Impact factor: 2.124

8.  Visible small-intestinal mucosal injury in chronic NSAID users.

Authors:  David Y Graham; Antone R Opekun; Field F Willingham; Waqar A Qureshi
Journal:  Clin Gastroenterol Hepatol       Date:  2005-01       Impact factor: 11.382

9.  Celecoxib exerts protective effects on extracellular matrix metabolism of mandibular condylar chondrocytes under excessive mechanical stress.

Authors:  S C Su; K Tanimoto; Y Tanne; R Kunimatsu; N Hirose; T Mitsuyoshi; Y Okamoto; K Tanne
Journal:  Osteoarthritis Cartilage       Date:  2014-04-08       Impact factor: 6.576

10.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Authors:  N Bhala; J Emberson; A Merhi; S Abramson; N Arber; J A Baron; C Bombardier; C Cannon; M E Farkouh; G A FitzGerald; P Goss; H Halls; E Hawk; C Hawkey; C Hennekens; M Hochberg; L E Holland; P M Kearney; L Laine; A Lanas; P Lance; A Laupacis; J Oates; C Patrono; T J Schnitzer; S Solomon; P Tugwell; K Wilson; J Wittes; C Baigent
Journal:  Lancet       Date:  2013-05-30       Impact factor: 79.321

View more
  2 in total

1.  Quantitative analysis of the mouth opening movement of temporomandibular joint disorder patients according to disc position using computer vision: a pilot study.

Authors:  Kug Jin Jeon; Young Hyun Kim; Eun-Gyu Ha; Han Seung Choi; Hyung-Joon Ahn; Jeong Ryong Lee; Dosik Hwang; Sang-Sun Han
Journal:  Quant Imaging Med Surg       Date:  2022-03

2.  Profiling of Patients with Temporomandibular Disorders: Experience of One Tertiary Care Center.

Authors:  Ema Vrbanović; Klara Dešković; Marko Zlendić; Iva Z Alajbeg
Journal:  Acta Stomatol Croat       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.